Cancer Treatment-Related Cardiotoxicity: Understanding the Current State of Knowledge and Developing Future Research Priorities

On this page...

Overview
Purpose
Agenda
Video Archive
Workshop Summary
Workshop Planning Committee

Need Help?

Have questions about this topic or need additional assistance?

Overview

The goals of anti-cancer therapies are to prevent recurrence, prolong life, and provide cure. Partly due to improvements in treatment, the population of cancer survivors is large and growing. However, cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in survivors of pediatric and adolescent cancers, after recurrence and second or subsequent malignancies. It is one of the most common post-treatment issues among five- to ten-year survivors of adult cancer. In addition, cancer patients may receive suboptimal therapy due to concern about potential cardiotoxicity, resulting in increased disease progression and mortality. The scientific knowledge gaps on cancer treatment-related cardiotoxicity are numerous, spanning basic and clinical science, and influence the advancement of science in this area. A joint effort of multiple disciplines within cardiology and oncology is required, thus this meeting includes leadership from the National Heart, Lung, and Blood Institute's (NHLBI) Division of Cardiovascular Sciences (DCVS) along with the National Cancer Institute's Divisions of Cancer Control and Population Sciences (DCCPS) and Cancer Prevention (DCP).

Purpose

This meeting brought together multiple disciplines within cardiology and oncology to identify research priorities aimed at improving the cardiac outcomes of cancer survivors. Research in cancer treatment-related cardiotoxicities is dependent on research in all other aspects of cardiotoxicity, as well as the development of new therapies, screening, and treatments that will impact the epidemiology and genomics of cardiotoxicity. The goal of this meeting was to identify research priorities in the area of cancer treatment-related cardiotoxicity to inform program announcements, other funding initiatives, and opportunities, and review articles describing current gaps and priorities for this important research area.

Agenda

View agenda for Wednesday, March 20, 2013

Wednesday, March 20	Topic
8:00 a.m. - 8:30 a.m.	Registration
Workshop Introductions and Overview Moderator: Joanna Brell, MD, Division of Cancer Prevention (DCP), NCI
8:30 a.m. - 8:55 a.m.	Welcome and Introductions Robert T. Croyle, PhD Division of Cancer Control and Population Sciences (DCCPS), NCI Lori Minasian, MD DCP, NCI Michael Lauer, MD Director of Cardiovascular Sciences (DCVS), NHLBI
8:55 a.m. - 9:10 a.m.	Workshop Overview and Objectives Nonniekaye Shelburne, CRNP, MS, AOCN Epidemiology and Genomics Research Program (EGRP), DCCPS, NCI
9:10 a.m. - 9:25 a.m.	Cancer Treatment-Related Cardiotoxicity: How Big is the Problem? Andrew Freedman, PhD EGRP, DCCPS, NCI
9:25 a.m. - 9:40 a.m.	Basic Science of Cancer Treatment-Related Cardiotoxicity Thomas Force, MD Temple University
Session 1: The Biology and Mechanisms of Cancer Treatment-Related Cardiotoxicity Moderator: Bishow Adhikari, PhD, DCVS, NHLBI
9:40 a.m. - 10:00 a.m.	Mechanisms of Cancer Treatment-Related Cardiotoxicity: Similarities/Connections with Cardiovascular Disease Speaker: Aarif Khakoo, MD Stanford University School of Medicine, Amgen
10:00 a.m. - 10:15 a.m.	Contemporary Agents in Cancer Treatment-Related Cardiotoxicity Speaker: Edward Yeh, MD The University of Texas MD Anderson Cancer Center
10:15 a.m. - 10:30 a.m.	Combination Cancer Therapy: The Cardiac Impact of Adding New Agents to Old Regimens Speaker: Bonnie Ky, MD, MSCE Abramson Cancer Center of the University of Pennsylvania
10:30 a.m. - 10:45 a.m.	BREAK
10:45 a.m. - 11:00 a.m.	Implications of Making a New Compound with Cardiotoxicity Potential: When Is the Toxicity Too Much? Speaker: Colin Dollery, FRCP GlaxoSmithKline
11:00 a.m. - 11:30 a.m.	Q&A / Open Discussion
11:30 a.m. - 12:00 p.m.	Session 1 Priority Setting
12:00 p.m. - 1:00 p.m.	LUNCH
Session 2: Preclinical Drug Development and Screening Moderator: Myrtle Davis Millin, DVM, PhD, Division of Cancer Treatment Diagnosis (DCTD), NCI
1:00 p.m. - 1:15 p.m.	Models for Drug Development and Screening Speaker: Kyle Kolaja, PhD Cellular Dynamics International
1:15 p.m. - 1:30 p.m.	What Animal Models Are Available to Inform Early Phase Therapeutics? Speaker: Thomas Force, MD Temple University
1:30 p.m. - 1:45 p.m.	The Role of Systems Biology in Cardiotoxicity Research Speaker: Darrell Abernethy, MD, PhD National Institute on Aging
1:45 p.m. - 2:00 p.m.	Drug Redesign: Animal Models Speaker: G.C. Teg Pipes, PhD GlaxoSmithKline
2:00 p.m. - 2:30 p.m.	Q&A / Open Discussion
2:30 p.m. - 3:00 p.m.	Session 2 Priority Setting
3:00 p.m. - 3:15 p.m.	BREAK
Session 3: Early Phase Therapeutics Moderator: Scot Remick, MD, West Virginia University Health Sciences Center
3:15 p.m. - 3:30 p.m.	Approach to Standardization of Safety/Screening Measurements and Toxicity Grading in Early Phase Clinical Trials Speaker: Daniel Lenihan, MD Vanderbilt University
3:30 p.m. - 3:45 p.m.	Applying metabolomics to cancer treatment related cardiotoxicity Speaker: Robert Gerzten, MD Massachusetts General Hospital
3:45 p.m. - 4:00 p.m.	Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives Speaker: Javid Moslehi, MD Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
4:00 p.m. - 4:15 p.m.	Bridging/Applying Mechanism of Cancer Treatment-Related Cardiotoxicity to Screening and Risk Prediction Speaker: Marielle Scherrer-Crosbie, MD, PhD Massachusetts General Hospital
4:15 p.m. - 4:35 p.m.	Q&A / Open Discussion
4:35 p.m. - 5:00 p.m.	Session 3 Priority Setting
5:00 p.m.	MEETING ADJOURNS

View agenda for Thursday, March 21, 2013

Thursday, March 21	Topic
8:00 a.m. - 8:30 a.m.	Registration
8:30 a.m. - 8:45 a.m.	Clinical Care of Cancer Treatment-Related Cardiotoxicity Speaker: Kevin Oeffinger, MD Memorial Sloan-Kettering Cancer Center
Session 4: Cancer Treatment-Related Cardiotoxicity: Risk, Screening, & Detection Moderator: Ming Hui Chen, MD, Brigham and Women's Hospital, Harvard Medical School
8:45 a.m. - 9:00 a.m.	Epidemiology of Hypertension and Heart Muscle Toxicity in Cancer Care Speaker: Michael Maitland, MD, PhD University of Chicago Medicine
9:00 a.m. - 9:15 a.m.	Pre-Treatment Risk Assessment of Cardiotoxicity: Pharmacogenomics Speaker: Smita Bhatia, MD, MPH City of Hope
9:15 a.m. - 9:30 a.m.	Clinical Biomarkers in Primary Heart Failure: Detecting Asymptomatic Toxicity Speaker: G. Michael Felker, MD, MHS Duke University School of Medicine
9:30 a.m. - 9:45 a.m.	Clinical Biomarkers in Cancer Treatment-Related Cardiotoxicity: Detecting Asymptomatic Toxicity Speaker: Jean-Bernard Durand, MD University of Texas MD Anderson Cancer Center
9:45 a.m. - 10:00 a.m.	BREAK
10:00 a.m. - 10:15 a.m.	Clinical Imaging: Detecting Asymptomatic Toxicity Speaker: Juan Carlos Plana, MD Cleveland Clinic
10:15 a.m. - 10:30 a.m.	The Patient's Perspective Speaker: Neeraj Arora, PhD Applied Research Program (ARP), DCCPS, NCI
10:30 a.m. - 11:00 a.m.	Q&A / Open Discussion
11:00 a.m. - 11:30 a.m.	Session 4 Priority Setting
11:30 a.m. - 12:30 p.m.	LUNCH
Session 5: Cancer Treatment-Related Cardiotoxicity: Prevention & Treatment Moderator: Alice Mascette, MD, DCVS, NHLBI
12:30 p.m. - 12:45 p.m.	Pharmacologic Methods for Prevention and Treatment of Hypertension Speaker: Philip Sager, MD Sager Consulting Partners
12:45 p.m. - 1:00 p.m.	Pharmacologic Methods for Prevention & Treatment of Heart Muscle Toxicity Speaker: Roberta Gottlieb, MD San Diego State University
1:00 p.m. - 1:15 p.m.	Pharmacologic Methods for Prevention of Cardiotoxicity in Breast Cancer Speaker: Maya Guglin, MD, PhD University of South Florida
1:15 p.m. - 1:30 p.m.	Cardiovascular Exercise and Biomarkers in Cancer Survivors Speaker: Jennifer Klemp, PhD, MPH University of Kansas Medical Center
1:30 p.m. - 1:45 p.m.	Nutrition in the Prevention and Treatment of Cancer Treatment-Related Cardiotoxicity Speaker: Wendy Demark-Wahnefried, PhD, RD University of Alabama
1:45 p.m. - 2:15 p.m.	Q&A / Open Discussion
2:15 p.m. - 2:45 p.m.	Session 5 Priority Setting
2:45 p.m. - 3:00 p.m.	BREAK
Session 6: Establishing Cohorts and Translating Findings Moderator: Richard Steingart, MD, Memorial Sloan-Kettering Cancer Center
3:00 p.m. - 3:15 p.m.	Barriers in the Development of Cancer Treatment-Related Cardiotoxicity Guidelines Speaker: JoAnn Lindenfeld, MD University of Colorado Hospital
3:15 p.m. - 3:30 p.m.	Establishing Cardiotoxicity Cohorts: Learning from the CCSS Speaker: Gregory Armstrong, MD, MSCE St. Jude Children's Research Hospital
3:30 p.m. - 3:45 p.m.	NCI Cardiovascular Toxicities Panel Recommendations Speaker: Scot Remick, MD West Virginia University Health Sciences Center
3:45 p.m. - 4:00 p.m.	Q&A / Open Discussion
4:00 p.m. - 4:15 p.m.	Session 6 Priority Setting
4:15 p.m. - 5:00 p.m.	Review and Vote on Research Priorities
5:00 p.m.	MEETING ADJOURNS

Video Archive

Workshop Summary

Cancer Treatment-Related Cardiotoxicity: Current State of Knowledge and Research Priorities. JNCI. 2014; 106(8).

Workshop Planning Committee

Scot Remick, MD, FACP - co-chair, West Virginia University
Thomas Force, MD - co-chair, Vanderbilt University
Nonniekaye Shelburne, CRNP, MS, AOCN - NCI, Division of Cancer Control and Population Sciences
Andrew Freedman, PhD - NCI, Division of Cancer Control and Population Sciences
Lori Minasian, MD, FACP - NCI, Division of Cancer Prevention
Patrice Desvigne-Nickens, MD - NHLBI, Division of Cardiovascular Sciences
Bishow Adhikari, PhD - NHLBI, Division of Cardiovascular Sciences
Myrtle Davis-Millin, DVM, PhD - NCI, Division of Cancer Treatment Diagnosis

Return to Events

Last Updated: 26 Apr, 2024